These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 29599087)
41. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Munoz FM Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956 [TBL] [Abstract][Full Text] [Related]
42. Immunogenicity of recombinant measles vaccine expressing fusion protein of respiratory syncytial virus in cynomolgus monkeys. Sawada A; Yunomae K; Nakayama T Microbiol Immunol; 2018 Feb; 62(2):132-136. PubMed ID: 29194753 [TBL] [Abstract][Full Text] [Related]
43. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines. Fuentes S; Arenas D; Moore MM; Golding H; Khurana S Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627 [TBL] [Abstract][Full Text] [Related]
44. Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus). Grieves JL; Yin Z; Durbin RK; Durbin JE Comp Med; 2015 Aug; 65(4):315-26. PubMed ID: 26310461 [TBL] [Abstract][Full Text] [Related]
45. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131 [TBL] [Abstract][Full Text] [Related]
46. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice. Fu YH; Jiao YY; He JS; Giang GY; Zhang W; Yan YF; Ma Y; Hua Y; Zhang Y; Peng XL; Shi CX; Hong T Antiviral Res; 2014 May; 105():72-9. PubMed ID: 24560779 [TBL] [Abstract][Full Text] [Related]
47. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. Schmidt AC; McAuliffe JM; Murphy BR; Collins PL J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329 [TBL] [Abstract][Full Text] [Related]
48. Clinical and epidemiologic features of respiratory syncytial virus. Hall CB; Simőes EA; Anderson LJ Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683 [TBL] [Abstract][Full Text] [Related]
49. Advances in and the potential of vaccines for respiratory syncytial virus. Jorquera PA; Oakley KE; Tripp RA Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629 [TBL] [Abstract][Full Text] [Related]
50. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Valosky J; Hishiki H; Zaoutis TE; Coffin SE Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003 [TBL] [Abstract][Full Text] [Related]
51. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice. Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474 [TBL] [Abstract][Full Text] [Related]
52. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods. Smith TRF; Schultheis K; Broderick KE Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156 [TBL] [Abstract][Full Text] [Related]
53. Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field. Kulkarni PS; Hurwitz JL; Simões EAF; Piedra PA Viral Immunol; 2018 Mar; 31(2):195-203. PubMed ID: 29336703 [TBL] [Abstract][Full Text] [Related]
55. Gene-based vaccine approaches for respiratory syncytial virus. Loomis RJ; Johnson PR Curr Top Microbiol Immunol; 2013; 372():307-24. PubMed ID: 24362696 [TBL] [Abstract][Full Text] [Related]
56. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098 [TBL] [Abstract][Full Text] [Related]
57. A multifaceted approach to RSV vaccination. Blanco JCG; Boukhvalova MS; Morrison TG; Vogel SN Hum Vaccin Immunother; 2018 Jul; 14(7):1734-1745. PubMed ID: 29771625 [TBL] [Abstract][Full Text] [Related]
58. Characterization of Cotton Rat ( Green MG; Petroff N; La Perle KMD; Niewiesk S Comp Med; 2018 Feb; 68(1):31-40. PubMed ID: 29460719 [TBL] [Abstract][Full Text] [Related]
59. Animal models of respiratory syncytial virus infection. Taylor G Vaccine; 2017 Jan; 35(3):469-480. PubMed ID: 27908639 [TBL] [Abstract][Full Text] [Related]
60. Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape. Oti VB; Idris A; McMillan NAJ Expert Rev Anti Infect Ther; 2024 Aug; 22(8):647-657. PubMed ID: 38973346 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]